Sarg has been shown to reduce serum urate in adenine and PO-induced hyperuricemia mice with nephropathy by suppressing the activation of nuclear factor-kappa B (NF-κB) and the Janus kinase/signal transducer and activator of transcription 3 (JAK/STAT3) signaling pathway, reducing inflammatory factor infiltration and urate accumulation in the kidney (Pan et al., 2021a). The gene discussed is STAT3; the disease is hyperuricemia.